Extremities Hospitals TissueGene, Inc. Announces FDA Acceptance Of Invossa™ As Proprietary Name For TissueGene-C byJosh SandbergJune 24, 2015
Extremities Hospitals TissueGene, Inc. Announces Special Protocol Assessment (SPA) Agreement with the Food and Drug Administration (FDA) for its Phase 3 Clinical Trial of Invossa™ for Patients Suffering from Osteoarthritis of the Knee byJosh SandbergMay 19, 2015
Recon TissueGene, Inc. Presents Phase 2 Data for Its Novel Cell Therapy for the Treatment of Osteoarthritis of the Knee byJosh SandbergMay 12, 2015
